New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
08:29 EDTSRPTSarepta's eteplirsen accelerated approval could be denied, TheStreet.com reports
According to TheStreet.com, accelerated approval for Sarepta's (SRPT) eteplirsen, a novel experimental drug for Duchenne Muscular Dystrophy, will be denied by the FDA. Instead, TheStreet says it is more likely Sarepta will be required to perform a larger pivotal study prior to submitting the drug for FDA review. Reference Link
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
13:51 EDTSRPTPotential Ebola patient being treated at UC Davis Medical Center, KCRA says
Subscribe for More Information
January 25, 2015
13:57 EDTSRPTUK nurse make full recovery from Ebola, WSJ says
Subscribe for More Information
January 23, 2015
10:02 EDTSRPTOn the Fly: Analyst Initiation Summary
Subscribe for More Information
January 22, 2015
16:15 EDTSRPTSarepta initiated with a Sector Perform at RBC Capital
Subscribe for More Information
January 21, 2015
10:01 EDTSRPTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:59 EDTSRPTSarepta downgraded to Neutral from Outperform at Wedbush
Subscribe for More Information
January 15, 2015
15:26 EDTSRPTSarepta says no safety info or comparison in BioMarin presentation
Sarepta (SRPT) said that, given the small sample size of study 201/202, the company understood the importance of providing an "extensive amount of date" in order to understand eteplirsen's treatment effect. Sarepta has reported mITT data since week 24 and has continued to provide updates on this same mITT at every timepoint, the company said. BioMarin's (BMRN) presentation on Monday focused on extension phase and excluded dose-escalation phase and results during off-treatment periods, according to Sarepta. "Sarepta has regularly reported complete 201/202 safety data on all patients. No safety information or comparison [was included] in BioMarin's Monday presentation," Sarepta wrote in slides for its presentation at the JPMorgan Healthcare Conference.
07:13 EDTSRPTJPMorgan to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use